Jordan Julie
Known title: Chief Medical OfficerCIK: 0001968554
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Q32 Bio to Present Late‑Breaking Results of Bempikibart Trial at EADV Congress. Q32 Bio will present late‑breaking results from Part B of its SIGNAL‑AA Phase 2a study of Bempikibart for alopecia areata at the European Academy of Dermatology and Venereology Congress. The company also shared additional 36‑week data from the same study earlier in the congress. These updates provide new information on the drug’s safety and efficacy profile, which may influence market perception of the company’s pipeline.
Transaction History
| NGNE | ▼ Sell | Open Market | 828 | $18K | 3/26/2026 | View on chart |
| NGNE | ▲ Buy | Grant | 4,900 | $0 | 2/20/2026 | View on chart |
| NGNE | ▲ Buy | Grant | 8,400 | $0 | 3/26/2025 | View on chart |
| QTTB | ▲ Buy | Option Exercise | 387 | $0 | 8/3/2023 | View on chart |
| QTTB | ▼ Sell | Open Market | 109 | $152 | 8/3/2023 | View on chart |
| QTTB | ▲ Buy | Option Exercise | 4,644 | $0 | 8/3/2023 | View on chart |
| QTTB | ▼ Sell | Open Market | 1,308 | $2K | 8/3/2023 | View on chart |
| QTTB | ▲ Buy | Option Exercise | 1,548 | $0 | 8/3/2023 | View on chart |
| QTTB | ▼ Sell | Open Market | 436 | $606 | 8/3/2023 | View on chart |
| QTTB | ▲ Buy | Option Exercise | 350 | $0 | 8/2/2023 | View on chart |
| QTTB | ▼ Sell | Open Market | 99 | $130 | 8/2/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Neurogene Announces Inducement Grants Under Nasdaq Rules
Neurogene disclosed that it issued inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is typically used to attract or retain key personnel without requiring shareholder approval. The announcement provides context for the stock's current position near its support level, though no new financial results or clinical data were released in this update.
Neurogene Announces Inducement Grants Under Nasdaq Rules. Neurogene disclosed that it issued inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is typically used to attract or retain key personnel without requiring shareholder approval. The announcement provides context for the stock's current position near its support level, though no new financial results or clinical data were released in this update.